Azafaros completes EUR25m Series A financing to advance rare metabolic disorders pipeline

This article was originally published here

This round was led by Forbion, with participation from BioMedPartners and founding investor BioGeneration Ventures (BGV). Azafaros was established in 2018 to translate innovative science from Leiden University

The post Azafaros completes EUR25m Series A financing to advance rare metabolic disorders pipeline appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply